Edition:
United Kingdom

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

0.48USD
22 Jun 2018
Change (% chg)

$-0.03 (-5.90%)
Prev Close
$0.51
Open
$0.51
Day's High
$0.52
Day's Low
$0.46
Volume
327,041
Avg. Vol
293,483
52-wk High
$2.83
52-wk Low
$0.33

Chart for

About

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to... (more)

Overall

Beta: 0.14
Market Cap(Mil.): $17.24
Shares Outstanding(Mil.): 9.85
Dividend: --
Yield (%): --

Financials

  ONTX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.62 -- --
ROI: -307.64 14.84 14.38
ROE: -4,335.58 16.34 16.08

BRIEF-Oleg Nodelman Reports 9.99 Pct Passive Stake In Onconova Therapeutics As Of April 27, 2018

* OLEG NODELMAN REPORTS 9.99 PERCENT PASSIVE STAKE IN ONCONOVA THERAPEUTICS INC, AS OF APRIL 27, 2018 - SEC FILING Source text: (https://bit.ly/2KJY3o0) Further company coverage:

07 May 2018

BRIEF-Onconova Therapeutics Announces Pricing Of $25 Mln Upsized Underwritten Public Offering

* ONCONOVA THERAPEUTICS ANNOUNCES PRICING OF $25.0 MILLION UPSIZED UNDERWRITTEN PUBLIC OFFERING

27 Apr 2018

BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting

* ONCONOVA PRESENTS DATA ON DUAL INHIBITOR OF CDK4/6 + ARK5 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL MEETING

19 Apr 2018

BRIEF-Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants

* ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT) Source text (https://bit.ly/2J0SqAg) Further company coverage:

17 Apr 2018

BRIEF-Onconova Therapeutics Reports Full-Year 2017 Results

* ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA

05 Mar 2018

BRIEF-683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics

* 683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING

16 Feb 2018

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

17 Jan 2018

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

04 Jan 2018

Competitors

Earnings vs. Estimates